ImmunoGen, Inc. (IMGN)
ImmunoGen has a market cap or net worth of $1.23 billion. The enterprise value is $874.46 million.
The next earnings date is Thursday, October 27, 2022, before market open.
|Estimated Earnings Date||Oct 27, 2022|
ImmunoGen has 217.53 million shares outstanding. The number of shares has increased by 26.74% in one year.
|Shares Change (YoY)||+26.74%|
|Shares Change (QoQ)||+0.03%|
|Owned by Insiders (%)||0.40%|
|Owned by Institutions (%)||92.08%|
|EV / Earnings||n/a|
|EV / Sales||9.78|
|EV / EBITDA||n/a|
|EV / EBIT||n/a|
|EV / FCF||n/a|
The company has a current ratio of 4.52, with a Debt / Equity ratio of 0.07.
|Debt / Equity||0.07|
|Debt / EBITDA||n/a|
|Debt / FCF||n/a|
Return on equity (ROE) is -67.00%.
|Return on Equity (ROE)||-67.00%|
|Return on Assets (ROA)||-37.20%|
|Return on Capital (ROIC)||n/a|
|Revenue Per Employee||$843,792|
|Profits Per Employee||-$1.52M|
|Effective Tax Rate||n/a|
Stock Price Statistics
The stock price has decreased by -2.73% in the last 52 weeks. The beta is 0.90, so ImmunoGen's price volatility has been lower than the market average.
|52-Week Price Change||-2.73%|
|50-Day Moving Average||5.34|
|200-Day Moving Average||4.80|
|Average Volume (30 Days)||2,941,342|
Short Selling Information
The latest short interest is 12.14 million, so 5.58% of the outstanding shares have been sold short.
|Short % of Shares Out||5.58%|
|Short % of Float||7.08%|
|Short Ratio (days to cover)||3.85|
In the last 12 months, ImmunoGen had revenue of $89.44 million and -160.68 million in losses. Earnings per share was -$0.59.
|Earnings Per Share (EPS)||-$0.59|
The company has $373.87 million in cash and $17.12 million in debt, giving a net cash position of $356.75 million or $1.64 per share.
|Cash & Cash Equivalents||373.87M|
|Net Cash Per Share||$1.64|
|Book Value Per Share||1.15|
In the last 12 months, operating cash flow was -$186.31 million and capital expenditures -$1.01 million, giving a free cash flow of -$187.32 million.
|Operating Cash Flow||-186.31M|
|Free Cash Flow||-187.32M|
|FCF Per Share||n/a|
Gross margin is 100.00%, with operating and profit margins of -170.72% and -179.64%.
Dividends & Yields
ImmunoGen does not appear to pay any dividends at this time.
|Dividend Per Share||n/a|
|Dividend Growth (YoY)||n/a|
The average price target for ImmunoGen is $11.43, which is 101.94% higher than the current price. The consensus rating is "Buy".
|Price Target Difference||101.94%|
This stock does not have any record of stock splits.
|Last Split Date||n/a|